Passage Bio Inc (PASG) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.95 (-1.79%), Market cap $0.02B, 52-week low–high $0.30 ~ $19.85.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agre
Financial statements, price targets, institutional (13F) holdings and related news for Passage Bio Inc are updated in real time on BlackAll Trade.
Passage Bio Inc trades at $4.95 (-1.79%). Real-time quotes and charts are available on BlackAll Trade.
Passage Bio Inc has a market cap of about $0.02B.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for th